Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of CAM2029 (Octreotide Subcutaneous Depot) in Acromegaly
2019-001191-11Phase 3Completed
- Sponsor
- Camurus
- Start
- Jun 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acromegaly comparing CAM2029 with Placebo (2 arms). Primary endpoint: Biochemical response based on IGF-1. Started Jun 2019; status: completed.
02
Drugs
octreotide hydrochloride
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2019-001191-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001191-11.